Benzinga··Vandana SinghGSK Expands RSV Vaccine Access to Younger High-Risk Adults, Broadening Market Opportunity
GSK's Arexvy RSV vaccine gains FDA approval for younger high-risk adults aged 18-49, expanding market beyond 60+ population on strong Phase 3b data and £198M Q4 sales.
GSKFDA approvalRSV vaccine